777 results on '"Szabo Gyongyi"'
Search Results
2. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
3. Prolonged hypoxia alleviates prolyl hydroxylation-mediated suppression of RIPK1 to promote necroptosis and inflammation
4. Randomized trial of anakinra plus zinc vs. prednisone for severe alcohol-associated hepatitis
5. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection
6. Inhibition of TLR8- and TLR4-induced Type I IFN induction by alcohol is different from its effects on inflammatory cytokine production in monocytes
7. Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis
8. Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling
9. Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcohol-associated hepatitis
10. Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH
11. Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest Group
12. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets
13. In vivo Bruton's tyrosine kinase inhibition attenuates alcohol-associated liver disease by regulating CD84-mediated granulopoiesis.
14. A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis.
15. Combined Insults of a MASH Diet and Alcohol Binges Activate Intercellular Communication and Neutrophil Recruitment via the NLRP3-IL-1β Axis in the Liver.
16. Role of non-Genetic Risk Factors in Exacerbating Alcohol-related organ damage
17. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
18. Immunopathobiology and therapeutic targets related to cytokines in liver diseases
19. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
20. Alcohol-related liver disease: Areas of consensus, unmet needs and opportunities for further study
21. Non-invasive diagnosis and biomarkers in alcohol-related liver disease
22. Bile acid–induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.
23. Abnormal neutrophil traps and impaired efferocytosis contribute to liver injury and sepsis severity after binge alcohol use
24. Sarcopenia is associated with longer hospital stay and multiorgan dysfunction in alcoholic hepatitis
25. Chronic alcohol-induced neuroinflammation involves CCR2/5-dependent peripheral macrophage infiltration and microglia alterations
26. G-CSF increases calprotectin expression, liver damage and neuroinflammation in a murine model of alcohol-induced ACLF.
27. Safety, Pharmacokinetics, and Efficacy Signals of Larsucosterol (DUR-928) in Alcohol-Associated Hepatitis.
28. Chapter 2 - Sinusoidal cell interactions—From soluble factors to exosomes
29. A novel score of IL-13 and age predicts 90-day mortality in severe alcohol-associated hepatitis: A multicenter plasma biomarker analysis.
30. Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-β
31. Dysregulated meta-organismal metabolism of aromatic amino acids in alcohol-associated liver disease.
32. Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis.
33. Alcoholic liver disease
34. Publisher Correction: Alcoholic liver disease
35. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice
36. Inflammasome activation in the liver: Focus on alcoholic and non-alcoholic steatohepatitis
37. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages
38. Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation.
39. Reduced gut microbiome protects from alcohol-induced neuroinflammation and alters intestinal and brain inflammasome expression
40. Role of MicroRNAs in NAFLD/NASH
41. Human Type 2 Myeloid Dendritic Cells Produce Interferon-λ and Amplify Interferon-α in Response to Hepatitis C Virus Infection
42. THU-330 Complement protein signatures in patients with alcohol-associated hepatitis
43. STING-IRF3 pathway links endoplasmic reticulum stress with hepatocyte apoptosis in early alcoholic liver disease
44. Clinical Trial Design for Alcoholic Hepatitis
45. Alcohol's effect on host defense
46. Mo1527 HIGH SERUM LEVELS OF INTERLEUKIN-10, MACROPHAGE COLONYSTIMULATING FACTOR AND SOLUBLE CD40L INDEPENDENTLY PREDICT 90-DAY MORTALITY IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS
47. Mo1526 ANAKINRA + ZINC TREATMENT IN PATIENTS WITH SEVERE ALCOHOLASSOCIATED HEPATITIS REDUCED SERUM CCL11 AND G-CSF IN A 28 DAY PERIOD: A MULTICENTER SERUM BIOMARKER ANALYSIS
48. IL-1α in acetaminophen toxicity: a sterile danger signal
49. Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known.
50. Type I Interferons Protect From Toll-Like Receptor 9–Associated Liver Injury and Regulate IL-1 Receptor Antagonist in Mice
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.